Loading...
First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
OBJECTIVES: Food and Drug Administration (FDA) approved crizotinib for advanced ROS1‐rearranged (ROS1+) non‐small‐cell lung cancer (NSCLC) patients due to a single‐arm study PROFILE 1001. However, there is no direct comparison between crizotinib and platinum‐pemetrexed chemotherapy. MATERIALS AND ME...
Na minha lista:
| Udgivet i: | Cancer Med |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7221427/ https://ncbi.nlm.nih.gov/pubmed/32167664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2972 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|